Latest News and Press Releases
Want to stay updated on the latest news?
-
Novotech CRO has released today two industry-leading reports on the Candidiasis and Rheumatoid Arthritis clinical trial landscapes.
-
Portland, OR, June 23, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Antifungal Drugs Market generated $16.6 billion in 2020, and is projected to...
-
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial...
-
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
-
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections ...
-
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
-
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
-
SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has...
-
SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing...
-
SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...